生物技术已率先进入心脏病的高血压药物的研制领域,原因是心脏病危及了大约6千5百万美国人,为此美国每年损失700多亿美元。事实上,目前美国制药工业投资和发展费用的25%以上已被应用于心血管病药物的研制。市场:Genentech’s Activase TissuePlasminogen Actiavtor(TPA)即组织型纤溶酶原激活剂是出现在市场上的第一种采用生物技术获得的治疗心脏病发作的药物。目前还有一些正处于临床试验阶段,其中包 Biotechnology has pioneered the development of heart-attacking antihypertensive drugs because of the devastating effects of heart disease on about 65 million Americans, for which the United States has lost more than $ 70 billion a year. In fact, more than 25% of the U.S. pharmaceutical industry’s investment and development costs have now been applied to the development of cardiovascular medicine. Market: Genentech’s Activase Tissue Plasminogen Actiavtor (TPA) tissue-type plasminogen activator is the first biologically available drug in the market to treat heart attacks. There are still some in the clinical trial phase, which package